New Delhi: After Hetero and Cipla, another pharmaceutical major Mylan was given permission by India's drug regulator on Thursday to manufacture and market the anti-viral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said.Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted.On June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions.The Union Health ministry in its 'Clinical Management Protocols for COVID-19' recommended the use of the drug in COVID-19 patients with moderate stages of the illness (those on.